Related Experiment Video
Updated: Jan 2, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Evaluation of apamin effects on myelination process in C57BL/6 mice model of multiple sclerosis
Maedeh Mohammadi-Rad1, Nazem Ghasemi2, Mehdi Aliomrani3
1Department of Toxicology and Pharmacology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.
Abstract:
Multiple sclerosis (MS) is a demyelinating disease that causes chronic inflammation in the central nervous system. The aim of this study was to investigate the effects of apamin administration on myelination process. MS was induced by feeding cuprizone pellets (0.2%) for 6 weeks (demyelination phase) followed by normal feeding for additional 2 weeks (remyelination phase). Briefly, C57BL/6 male mice were randomly divided into six groups. Group 1, received the regular food pellets. Group 2 contained two subgroups of 6 animals each (n = 2 × 6). First group received cuprizone for 6 weeks and the sacrificed while the second group after 6 weeks of cuprizone, received no treatment for additional 2 weeks. Group 3 (co-treatment group) was composed of two subgroups of 6 animals each (n = 2 × 6). Both subgroups received apamin (100 μg/kg) intraperitoneally twice a week for 6 weeks. First subgroup terminated at this time and the second subgroup was fed normal diet for two additional weeks. Group 4 (post-treatment, n = 6) received apamin (100 μg/kg) intraperitoneally twice a week for 2 weeks after cuprizone secession. Groups 5 and 6 (vehicle, n = 6 in each group) received phosphate buffered saline as the vehicle of apamin during demyelination and remyelination phase. At the end of each phase, mice were deeply anesthetized and perfused. Groups 5 and 6 (vehicle) received PBS as the vehicle during both phases. Mice were anesthetized, perfused with PBS through their heart, and their brains were removed. Brain sections stained with luxol fast blue and the images were analyzed. Apamin co-treatment significantly increased the myelin content as compared to the cuprizone group. Also, mild elevation in the myelinated areas was observed with apamin post-treatment in comparison with remyelination phase. Our results revealed that apamin prevents myelin destruction more significantly as compared to remyelination process. This observation explains the possible role of apamin in inhibiting the activation of the microglia cells than stimulation of the oligodendrocytic precursor cells.
Insights
Apamin administration in mice with multiple sclerosis (MS) showed it prevents myelin destruction more effectively than promoting remyelination. This suggests apamin may inhibit microglia activation, offering a potential therapeutic avenue for MS.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Multiple sclerosis (MS) is a central nervous system demyelinating disease characterized by chronic inflammation.
- Understanding the mechanisms of myelin destruction and repair is crucial for developing effective MS therapies.
Purpose of the Study:
- To investigate the effects of apamin on the myelination process in a mouse model of MS.
- To determine if apamin administration can prevent myelin damage or enhance remyelination.
Main Methods:
- Multiple sclerosis was induced in C57BL/6 mice using cuprizone.
- Mice were divided into groups receiving apamin during demyelination (co-treatment) or remyelination (post-treatment) phases.
- Brain sections were stained with luxol fast blue to analyze myelin content.
Main Results:
- Apamin co-treatment significantly increased myelin content compared to the cuprizone-only group.
- Apamin post-treatment showed a mild increase in myelinated areas during the remyelination phase.
- Apamin demonstrated a greater effect in preventing myelin destruction than in promoting remyelination.
Conclusions:
- Apamin exhibits a protective effect against myelin damage in MS, potentially by inhibiting microglia activation.
- The findings suggest apamin's therapeutic potential in managing MS by preserving myelin integrity.

